Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Average (2021 - 2025)

Historic Equity Average for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $1.2 billion.

  • Krystal Biotech's Equity Average rose 2866.51% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 2866.51%. This contributed to the annual value of $1.1 billion for FY2025, which is 2556.02% up from last year.
  • Per Krystal Biotech's latest filing, its Equity Average stood at $1.2 billion for Q4 2025, which was up 2866.51% from $1.1 billion recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Equity Average ranged from a high of $1.2 billion in Q4 2025 and a low of $413.4 million during Q3 2021
  • Its 5-year average for Equity Average is $722.5 million, with a median of $704.5 million in 2023.
  • As far as peak fluctuations go, Krystal Biotech's Equity Average crashed by 1141.14% in 2023, and later skyrocketed by 5594.86% in 2024.
  • Over the past 5 years, Krystal Biotech's Equity Average (Quarter) stood at $500.9 million in 2021, then grew by 6.11% to $531.5 million in 2022, then surged by 44.36% to $767.3 million in 2023, then rose by 19.4% to $916.1 million in 2024, then increased by 28.67% to $1.2 billion in 2025.
  • Its Equity Average was $1.2 billion in Q4 2025, compared to $1.1 billion in Q3 2025 and $1.0 billion in Q2 2025.